Affimed Logo.jpg
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
June 01, 2024 13:02 ET | Affimed N.V.
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing...
OFL_Logo_Colour_HORIZ_SCREEN.png
Union members and allies mark Injured Workers’ Day in locations across Ontario
June 01, 2024 12:55 ET | Ontario Federation of Labour
Ontario unions join injured workers and supporters at events across the province to mark Injured Workers' Day.
Prospera.png
Prospera Energy Inc. Announces 2023 Financial Results
June 01, 2024 12:36 ET | Prospera Energy Inc.
CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (PEI: TSX-V; OF6A: FRA) 2023 was a transformational year for Prospera transforming to...
La Journée des Films thaïlandais à Paris captive le public parisien avec une première prestigieuse PARIS, 01 juin 2024 (GLOBE NEWSWIRE) -- Le Journée des Films thaïlandais à Paris qui s’est tenue le 27 mai 2024 au prestigieux cinéma Publicis, sur les Champs-Élysées, a connu un succès...
Investigational Acas
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024 10:00 ET | BioNTech SE
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...
logo.jpg
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024 10:00 ET | Genmab A/S
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival...
Corbus Logo.jpg
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
June 01, 2024 10:00 ET | Corbus Pharmaceuticals Holdings, Inc.
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and...
BDTxLogo_PANTONE3135C_PNG.png
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2024 10:00 ET | Black Diamond Therapeutics, Inc
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...
OKX logo-black.png
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
June 01, 2024 09:14 ET | OKX
NASSAU, The Bahamas, June 01, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for June 1, 2024. OKX Announces...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
June 01, 2024 09:00 ET | ClearPoint Neuro, Inc.
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4